Rectal Cancer - Pipeline Review, H1 2018

  • ID: 4464916
  • Report
  • 112 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Advaxis Inc
  • Amgen Inc
  • Avid Bioservices Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • MORE
Rectal Cancer - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Rectal Cancer - Pipeline Review, H1 2018, provides an overview of the Rectal Cancer (Oncology) pipeline landscape.

Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The risk factors for developing rectal cancer are increasing age, smoking, family history of colon or rectal cancer, high-fat diet and/or a diet mostly from animal sources and personal or family history of polyps or colorectal cancer. Rectal cancer commonly spreads to organs such as the liver and the lungs. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood, either bright red or very dark in the stool, stools that are narrower than usual, general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps, weight loss with no known reason, constant tiredness and vomiting. Rectal cancer treatment includes surgery, radiation therapy or chemotherapy, or a combination of these approaches

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Rectal Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Rectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Rectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I and Discovery stages are 1, 6, 4 and 1 respectively.

Rectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourcedfrom the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rectal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Rectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rectal Cancer (Oncology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rectal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • Advaxis Inc
  • Amgen Inc
  • Avid Bioservices Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • MORE
Introduction

The Publisher's Report Coverage

Rectal Cancer - Overview

Rectal Cancer - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Rectal Cancer - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Rectal Cancer - Companies Involved in Therapeutics Development

AbbVie Inc

Advaxis Inc

Amgen Inc

Avid Bioservices Inc

Eisai Co Ltd

Eli Lilly and Co

GlaxoSmithKline Plc

Madrigal Pharmaceuticals Inc.

Merck KGaA

NewLink Genetics Corp

Taiwan Liposome Company Ltd

Rectal Cancer - Drug Profiles

AK-109 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

axalimogene filolisbac - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bavituximab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bevacizumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CRLX-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

E-7046 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

galunisertib monohydrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ganetespib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2256098 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

M-7824 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TLC-388 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veliparib ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Rectal Cancer - Dormant Projects

Rectal Cancer - Product Development Milestones

Featured News & Press Releases

Apr 23, 2014: Abbvie To Present Data On Veliparib At The 2014 American Society Of Clinical Oncology Annual Meeting

Nov 10, 2011: Synta Announces Results Show Ganetespib Sensitizes Rectal Cancer Cells To Chemoradiotherapy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Rectal Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Rectal Cancer - Pipeline by AbbVie Inc, H1 2018

Rectal Cancer - Pipeline by Advaxis Inc, H1 2018

Rectal Cancer - Pipeline by Amgen Inc, H1 2018

Rectal Cancer - Pipeline by Avid Bioservices Inc, H1 2018

Rectal Cancer - Pipeline by Eisai Co Ltd, H1 2018

Rectal Cancer - Pipeline by Eli Lilly and Co, H1 2018

Rectal Cancer - Pipeline by GlaxoSmithKline Plc, H1 2018

Rectal Cancer - Pipeline by Madrigal Pharmaceuticals Inc., H1 2018

Rectal Cancer - Pipeline by Merck KGaA, H1 2018

Rectal Cancer - Pipeline by NewLink Genetics Corp, H1 2018

Rectal Cancer - Pipeline by Taiwan Liposome Company Ltd, H1 2018

Rectal Cancer - Dormant Projects, H1 2018

List of Figures

Number of Products under Development for Rectal Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Advaxis Inc
  • Amgen Inc
  • Avid Bioservices Inc
  • Eisai Co Ltd
  • Eli Lilly and Co
  • GlaxoSmithKline Plc
  • Madrigal Pharmaceuticals Inc.
  • Merck KGaA
  • NewLink Genetics Corp
  • Taiwan Liposome Company Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll